{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:45Z","timestamp":1790894445411,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["NCT02466243"],"award-info":[{"award-number":["NCT02466243"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014025","name":"Dorrance Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xjidi.2024.100311","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T19:53:55Z","timestamp":1725652435000},"page":"100311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1697-1659","authenticated-orcid":false,"given":"Caroline J.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-7659","authenticated-orcid":false,"given":"Geeta","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-4362","authenticated-orcid":false,"given":"Lais","family":"Lopes Almeida Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1544-9640","authenticated-orcid":false,"given":"Joy","family":"Poroye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-9352","authenticated-orcid":false,"given":"Daniella Forman","family":"Faden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2163-5170","authenticated-orcid":false,"given":"Lillian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-7228","authenticated-orcid":false,"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-665X","authenticated-orcid":false,"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100311_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study","volume":"141","author":"Ang","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1521-6616(03)00064-0","article-title":"Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes","volume":"108","author":"Bidinger","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100311_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100311_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100311_bib7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/acr.24980","article-title":"Cessation of immunomodulatory medication use in dermatomyositis: a single-center cohort study","volume":"75","author":"Cho","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.xjidi.2024.100311_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48\u201349","author":"Iaccarino","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.xjidi.2024.100311_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13075-021-02665-x","article-title":"Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in\u00a0vivo effects of LenabasumTM","volume":"24","author":"Maddukuri","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2024.100311_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of Anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xjidi.2024.100311_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.jid.5700212","article-title":"Testing and reducing skindex-29 using Rasch analysis: Skindex-17","volume":"126","author":"Nijsten","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib12","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum Phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib13","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and Type I interferons in dermatomyositis in\u00a0vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib16","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J\u00a0Neuroimmune Pharmacol"},{"key":"10.1016\/j.xjidi.2024.100311_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xjidi.2024.100311_bib18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a Phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.55563\/clinexprheumatol\/i80zh7","article-title":"A\u00a0randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale","volume":"39","author":"Spiera","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899526","article-title":"Autoimmune skin disease exacerbations following COVID-19 vaccination","volume":"13","author":"Sprow","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2024.100311_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.lfs.2008.09.004","article-title":"Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells","volume":"83","author":"Stebulis","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.xjidi.2024.100311_bib22","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100311_bib23","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2024.100311_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xjidi.2024.100311_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1096\/fj.08-118323","article-title":"Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4","volume":"23","author":"Zurier","year":"2009","journal-title":"FASEB J"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:56:44Z","timestamp":1736524604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2667026724000584"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100311","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100311"}}